Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + zoledronic acid
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Subcutaneous
01
Overview
Methotrexate is an antimetabolite and immunosuppressant that inhibits enzymes responsible for nucleotide synthesis, thereby reducing cell division and inflammation. It is widely used in rheumatoid arthritis, psoriasis, and certain cancers[6][9]. Zoledronic acid is a bisphosphonate that inhibits osteoclast function, preventing bone resorption. It is used to treat osteoporosis, hypercalcemia of malignancy, multiple myeloma, and bone metastases from solid tumors[5]. The combination of methotrexate and zoledronic acid has been studied for its potential to prevent both bone erosion (via anti-inflammatory effects) and systemic bone loss (via direct osteoclast inhibition), particularly in models of rheumatoid arthritis[1]. In clinical trials for advanced cancer with bone involvement (e.g., osteosarcoma), this combination has also been explored alongside other agents such as cyclophosphamide and sirolimus[3][7].
- Other names
- MTX + ZAmethotrexate and zoledronic acid
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on methotrexate + zoledronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + zoledronic acid.